Why Is ABIVAX SA ADR (ABVX) Stock Moving Today?

Why ABVX stock is down today

ABVX stock fell 5.12% to $98.15 in early trading on September 21, 2026, following a mix of bearish analyst updates and the release of first-half 2026 financial results. The stock opened at $103.31 and steadily declined throughout the session, reaching a low of $97.68 before settling near $98.22. The move reflects investor concern over the company’s performance and revised expectations from analysts.

What Happened

The stock’s decline came after Wedbush and Truist both cut their price targets for ABVX. Wedbush reduced its target to $118 from $140, while Truist lowered its target to $151 from $155. These adjustments followed the company’s first-half 2026 financial results, which showed continued unprofitability with a trailing twelve-month (TTM) earnings per share of -5.23 and a TTM revenue decline of 59.8%. In addition, Abivax announced key leadership changes, including the appointment of Chris Rabbat as Chief Medical Officer, succeeding Fabio Cataldi. The stock also opened the session with a bearish tone, as options data had previously suggested a potential 6.0% move post-earnings.

What The Data Shows

The stock has been under pressure recently, with a downward trend of -6.0% over the last eight sessions. Trading volume was elevated at 0.6 million shares, or 0.3 times the 3-month average. The stock closed near its session low and has now printed 11 fresh 52-week lows on September 22. The broader market context included a general improvement in investor sentiment, though the Nasdaq’s weekly gains did not extend to ABVX. Meanwhile, retail chatter remained muted, with no significant social media activity reported in the last 24 hours.

What To Watch

The stock is set to report earnings on September 21, 2026, which could provide further insight into the company’s performance and strategic direction. Investors will also be watching for additional analyst coverage and how the stock reacts to the recent leadership changes and bearish price target revisions.